Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...
Antibody-drug conjugate (RG6109) Antibody-drug conjugate (RG6148) Anti-MUC16 TDC (RG7882) Anti-TIGIT MAb (MTIG7192A, RG6058) Atezolizumab (anti-PDL1 MAb) (RG7446) BET inhibitor (TEN-010, RG6146) Bevacizumab (anti-VEGF Mab) CD20 TCB (RG6026) CD20 TDB (RG7828) CEA TCB (RG7802) Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) Codrituzumab (anti–glypican-3 MAb) (GC33, RG7686) Emactuzumab (anti–CSF-1R MAb) (RG7155) Entrectinib FAP-DR5 biMAb (RG7386) FAP-IL2v FP (RG7461) Glypican-3/CD3 biMAb (CHU) Idasanutlin (MDM2 antagonist) (RG7388) Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) Monoclonal antibody (RG6160) Monoclonal antibody (RG6194) Obinutuzumab Pan-RAF inhibitor (RG6185) Personalized cancer vaccine (RG6180) PI3K inhibitor (GDC-0077, RG6114) Polatuzumab vedotin (anti-CD79b ADC) (RG7596) Raf/MEK dual inhibitor Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) Selicrelumab (anti-CD40 MAb) (RG7876) Taselisib (PI3K inhibitor) (GDC-0032, RG7604) Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601)

US Region

International

Region

Select...
Clear All
View Results
Expand +

Tumor Type: Hematology

Phase: PHASE I

Region: Midwest

Molecule:

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab MN NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab MN
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IL NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IL
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) MI NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) MI
NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) MO NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) MO
NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) MO NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) MO
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MI NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MI
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MO NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MO
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MI NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MI
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IL NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IL
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
1 of 11 clinical trials
1-4 of 11 clinical trials
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
The list of international studies is not comprehensive; only international studies that also include actively enrolling US sites are listed.

Click "OK" if you wish to proceed.
CancelOK